Introduction {#sec1}
============

Neuromuscular disorders are a group of heterogeneous diseases leading to muscle wasting and weakness.[@bib1] Several promising treatment strategies using pharmaco-gene therapies have emerged for some of them, including Duchenne muscular dystrophy (DMD).[@bib2], [@bib3], [@bib4] DMD patients present mutations in the dystrophin gene, leading to an absence of the dystrophin protein. The consequences are a progressive muscle degeneration and weakness. Recently, 2 oligo-antisense drugs, eteplirsen and golodirsen, were approved by the US Food and Drug Administration (FDA), and several clinical trials are ongoing, including 3 systemic adeno-associated virus (AAV) trials administering microdystrophin for DMD ("ClinicalTrials.gov: [NCT03368742](NCT03368742){#intref0010}, [NCT03362502](NCT03362502){#intref0015}, and [NCT03375164](NCT03375164){#intref0020}").

Primary endpoints for clinical trials using pharmaco-gene therapy commonly use clinical scales, such as the North Star Ambulatory Assessment; timed tests, such as the 6-min walk test; or respiratory measures, such as Forced Vital Capacity.[@bib5], [@bib6], [@bib7], [@bib8] These measures suffer from important methodological limitations, such as dependence on motivation and floor and ceiling effects for individual items, and importantly, also show age-related or nonlinear behavior over the disease time course, such as evidenced for loss of ambulation with drastic deterioration of 6 minute walk test (MWT) performances.[@bib9]^,^[@bib10] These shortcomings are only partially compensated by quantifiable secondary or exploratory endpoints, such as muscle magnetic resonance imaging (MRI),[@bib11] which does not provide a quantitative summary readout for the whole neuromuscular system.

To overcome this limitation, molecular biomarkers have also been proposed (for review, see Wilson et al.[@bib12]), but the quantification of some of these biomarkers, such as dystrophin, needs invasive investigations (muscle biopsy) and are limited to the small sampled area, and their quantitative relation to a clinically observable treatment response remains to be established.

Ideally, easily accessible circulating biomarkers, which in a quantitative and robust manner reflect the state of muscle well-being, would be preferable for noninvasive monitoring of treatment effects and should be applicable across the entire range of clinical severity of affected patients. To that effect, promising results have been obtained for serum biomarkers, such as myomesin-3 or serum or urine titin, or for a host of microRNAs (miRNAs), in particular, the muscle-specific miRNAs (myomiRs) in DMD (for review, see Aartsma-Rus and Spitali[@bib13]). All of the above biomarkers suffer from quite variable ranges across individuals with different epigenetic background and disease-states, and directly or indirectly reflect specific parts of the pathogenetic process such as degradation of the elastic sarcomere scaffold in DMD (myomesin-3, titin) or inflammatory aspects of the disease (miRNAs). None of these molecules has been validated as biomarkers for monitoring drug response.

Here, we investigated if circulating myostatin (Mstn) could be a quantitative biomarker for treatment efficacy in DMD. Mstn is a secreted protein, produced and released by the skeletal muscle, which acts as an inhibitor of muscle growth.[@bib14] We have previously demonstrated that circulating Mstn levels are dramatically reduced in patients affected by a muscle wasting or atrophying disease, both in the human and in preclinical models of myotubular myopathy.[@bib15] In particular, we observed that whereas intramuscular (i.m.) levels of Mstn are dramatically low in the Mtm1 knockout (KO) mouse model for X-linked myotubular myopathy, AAV-Mtm1 gene therapy leads to an increase of Mstn and to the decrease of its natural inhibitor, follistatin. This suggested that the Mstn pathway expression could be used to monitor muscle health and disease, therefore opening the possibility for essential effectors of this pathway (Mstn, activin receptors, follistatin, etc.) to reflect quantitatively the effects of therapy in neuromuscular patients.

In this study, we have investigated this hypothesis in the Golden Retriever muscular dystrophy (GRMD) canine model for DMD and DMD-treated patients. Indeed, we have recently demonstrated that locoregional or systemic administration of an AAV vector coding a canine microdystrophin (cMD1) reduces the physiological decline in muscle strength/function of treated limbs in the treated animals in a dose-dependent manner.[@bib3] Here, we show that in dogs, Mstn levels were sufficient to distinguish control, untreated, low-dose-, and high-dose-treated GRMD dogs, confirming the results obtained in clinical evaluation and in the muscle dystrophin quantitation. These data show that circulating Mstn is a reliable and quantitative biomarker for short- and long-term monitoring of therapy effects in DMD and may be in other neuromuscular patients.

Results {#sec2}
=======

Circulating Levels of Mstn in Control and GRMD Dogs {#sec2.1}
---------------------------------------------------

Mstn circulating serum concentrations were determined in control dogs or dogs affected by dystrophin deficiency (GRMD) at different ages, starting at 2 months ([Figure 1](#fig1){ref-type="fig"}A). In control animals, Mstn levels increased until the age of 10 months, when a plateau was reached. In the GRMD dogs, Mstn levels rapidly decreased, and already at 6 months, the minimum value was reached. Whereas the data in the wild-type (WT) animals showed some variability, the levels observed in GRMD dogs are highly homogeneous, and the two cohorts never overlap after the age of 2 months ([Figure 1](#fig1){ref-type="fig"}A). At the age of 2 months, Mstn levels are similar in the WT and GRMD animals (13,173 pg/mL ± 4,008 versus 12,138 pg/mL ± 3,103, respectively, p \> 0.05), but at 4 months, the measure of circulating Mstn is sufficient to distinguish WT and GRMD animals (14,960 pg/mL ± 3,905 versus 7,350 pg/mL ± 2,140, respectively, p = 0.03), and at 6 months, the difference is even larger (16,582 pg/mL ± 1,794 versus 5,924 pg/mL ± 2,463, respectively, p = 0.003) ([Figure 1](#fig1){ref-type="fig"}A). Some of the GRMD dogs were clinically stratified as moderate (n = 10) or severe (n = 4) disease progressors, according to the ambulatory status at the age of 6 months (ambulant versus nonambulant, respectively).[@bib16] The levels of circulating Mstn were not significantly different between moderate and severe progressors at the ages of 2, 4, and 6 months ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 1Myostatin Expression in GRMD and WT Dogs(A) Mstn levels were measured in both WT and GRMD dogs at different ages. (B--D) mRNA expression of *Mstn* (B), *Acvr2b* (C), and *Fstn* (D) was measured in WT, GRMD-moderate, and GRMD-severe dogs at different ages. The number of samples for each point is detailed in [Table S1](#mmc1){ref-type="supplementary-material"}. Error bars are SD (no SD when n \< 3).

Mstn Pathway mRNA Levels in Control and GRMD Dogs {#sec2.2}
-------------------------------------------------

*Mstn* expression was next measured at the mRNA level in biceps femoris and sartorius muscle biopsies at different ages ([Figures 1](#fig1){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}). In the WT animals, *Mstn* levels slightly increased over time, whereas in the GRMD animals, a significant decrease was observed in the first months of age to reach minimum levels, which are maintained until 40 months ([Figure 1](#fig1){ref-type="fig"}B). No difference was noted between moderate and severe GRMD disease progressors. These results confirmed the observations made in the sera. The mRNA levels of other components of the Mstn pathway were also measured. At the age of 6 months, a lower expression of the Mstn receptor *Acvr2b* was observed in the GRMD dogs compared to the WT animals (1.48 ± 0.46 for the WT, 0.95 ± 0.23 for the moderate progressor, and 1.06 ± 0.06 for the severe progressor; [Figure 1](#fig1){ref-type="fig"}C) associated with a higher expression of the Mstn antagonist *Fstn* (0.23 ± 0.05 for the WT, 0.43 ± 0.01 for the moderate progressor, and 0.95 ± 0.9 for the severe progressor; [Figure 1](#fig1){ref-type="fig"}D). In the sartorius muscle, similar expression patterns were observed ([Figure S2](#mmc1){ref-type="supplementary-material"}). These results demonstrated the shutdown of the Mstn pathway in the GRMD dogs at both protein and at mRNA levels in the serum and skeletal muscle tissue. respectively. Mstn may therefore be a reliable biomarker of the anabolic homeostatic state of the muscular tissue. The GRMD dog is thus a good model to evaluate if components of the Mstn pathway may be used as biomarkers of therapeutic efficacy for systemic therapies in DMD.

Mstn Is a Biomarker to Monitor Drug Response in GRMD Dogs {#sec2.3}
---------------------------------------------------------

Circulating Mstn levels were assessed in GRMD dogs, locoregionally or systemically treated with a recombinant AAV2/8 (rAAV2/8) vector coding a cMD1, as described previously.[@bib3] After loco-regional (1e13 vg/kg) or low-dose intravenous (i.v.) injection (2e13 vg/kg), no modification of circulating Mstn was observed ([Figure 2](#fig2){ref-type="fig"}A). After high-dose i.v. injection (1e14 vg/kg), levels of circulating Mstn increased significantly above baseline level but remained below the levels of healthy animals. GRMD serum Mstn levels were maintained until the age of 18 months, when they started to decline ([Figure 2](#fig2){ref-type="fig"}A). One possible explanation for this decrease is the progressive clearance of the AAV-mediated transgene in a continuously regenerating muscle, leading to a lowered expression of cMD1. A larger number of samples would be necessary to answer this question definitely.Figure 2Myostatin Expression in AAV-cDM1-Treated GRMD Dogs(A) Mstn levels were measured in blood samples isolated from either WT or GRMD dogs injected via loco-regional route (LR) or systemic i.v. (IV) routes with a high (1e14 vg/kg) or low (2e13 vg/kg) dose of the AAV vector coding a sequence-optimized cMD1. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, Student's t test, compared to untreated GRMD dogs. (B) 3- to 4-month-old GRMD dogs (n = 4) were loco-regionally treated with 1e13 vg/kg, and *Mstn*, *Fstn*, and *Acv*r*2b* were analyzed at mRNA levels in muscle biopsies, 2 and 4 months after treatment. For each mRNA, results are expressed as the ratio, injected leg/noninjected leg. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001, Student's t test. (C) *Mstn* (black), *Fstn* (gray), *AcvR2b* (*ActivinR2b*; white), and *cMD1* (diamond) mRNA levels were analyzed in untreated or low- or high-dose i.v.-treated GRMD animals at the age of 10 months. The transcript amounts were normalized using *Rpl32* dog ribosomal RNA. Treated dogs were AAV injected at the age of 2--2.5 months. The number of samples for each point is detailed in [Table S1](#mmc1){ref-type="supplementary-material"}. Error bars are SEM. A one-way ANOVA, followed by Newman-Keuls test was performed.

The levels of different components of the Mstn pathway were also evaluated on muscle biopsies at mRNA levels. The expression levels of *Mstn*, *Fstn*, and *Acvr2b* were compared in 4 loco-regionally injected and in untreated leg muscles. Because we had access to muscle biopsies harvested, 2 and 4 months after injection (T1 and T2 respectively) but not before injection, we calculated a ratio-injected limb/noninjected limb for each gene in each dog's extensor carpi radialis muscle ([Figure 2](#fig2){ref-type="fig"}B). This ratio was 2.7 ± 1 at T1 (p = 0.03) and 3.5 ± 1.3 at T2 (p = 0.05) for *Mstn*. This shows that *Mstn* is significantly expressed at higher levels in the treated leg, thus demonstrating that dystrophin rescue induces *Mstn* re-expression at the mRNA level. Indeed, the mean percentage of cMD1-positive fibers was 50% in the treated forelimb and 2% in the noninjected one.[@bib17] This observation is also true for *Fstn* and *Acvr2b*, which are also increased subsequent to microdystrophin therapy but to a lesser extent (T1: 1.26 ± 0.21 and 1.33 ± 0.07; T2: 1.36 ± 0.31 and 1.33 ± 0.3, respectively).

The Mstn network was also analyzed after systemic injection in 10-month-old dogs, treated with either 2e13 vg/kg or 1e14 vg/kg and compared to age-matched untreated dogs ([Figure 2](#fig2){ref-type="fig"}C). No difference in *Mstn* mRNA was observed in the untreated and 2e13 vg/kg-treated animals (0.12 ± 0.068 and 0.11 ± 0.03, respectively), whereas in high-dose-treated animals, *Mstn* levels were increased two-fold (0.25 ± 0.1; p = 0.06). Expression levels of either *Fstn* or *Acvr2b* did not show a modification of expression in the treated animals. The Mstn pathway was thus reactivated in the high-dose-treated animals only, where cMD1 is also expressed ([Figures 2](#fig2){ref-type="fig"}C).Figure 3Mstn Pathway in DMD Patients Intramuscularly Treated with AVI-4658 PMO (PMO)Patients 6 and 7 have been described previously.[@bib18] mRNA levels of *MSTN*, *FSTN*, *ACVR2B*, and *ATROGIN* have been analyzed by quantitative real-time PCR in both AVI-4658 PMO and saline-injected (sal.) EDBs.

Mstn Levels in DMD Patients Treated i.m. with Morpholino-Induced Exon 51 Skipping {#sec2.4}
---------------------------------------------------------------------------------

Mstn levels were next measured in the muscle biopsies of DMD patients, intramuscularly treated with the morpholino (phosphorodiamidate morpholino oligomer \[PMO\]) antisense oligonucleotide AVI-4658 (eteplirsen) that induces skipping of exon 51 in dystrophin mRNA.[@bib18] Seven patients were previously treated during the trial ("ClinicalTrials.gov: [NCT00159250](NCT00159250){#intref0025}"), but we only had access to the biopsies of 2 patients who received 0.9 mg intramuscular eteplirsen in one extensor digitorum brevis (EDB) muscle. *MSTN*, *FSTN*, *ACVR2B*, and *ATROGIN* expressions were analyzed in the PMO and saline-treated muscles, 3 (patient 6) or 4 (patient 7) weeks after treatment, and correlated with dystrophin levels. The PMO-treated muscles did not show a difference in the mRNA levels of these genes compared to the saline-treated ones ([Figure 3](#fig3){ref-type="fig"}). Of note, only a limited amount of dystrophin was expressed (63%--65% of dystrophin-positive fibers with a relative intensity of 22%--25% of that in healthy muscle),[@bib18] in contrast to the \>50% microdystrophin expression in GRMD muscles where Mstn was partially rehabilitated,[@bib3] suggesting that certain threshold levels of correction have to be achieved in order to restore intramuscular Mstn.

Discussion {#sec3}
==========

In our study, we evaluated MSTN as a biomarker for treatment efficacy in DMD. Indeed, we had previously observed low levels of serum MSTN in these patients.[@bib15] Furthermore, our results indicated that the regulation of the Mstn network was, at least partly, driven by muscle atrophy/inactivity, because patients affected by the most atrophying conditions showed the strongest downregulation of the Mstn pathway. In the present study, we demonstrate that Mstn was significantly increased following treatment with a disease-modifying drug, which further validates Mstn as a biomarker.

Because we could not have access to serum from systemically treated DMD patients in current clinical trials, we used samples generated in preclinical microdystrophin trials conducted in 12 GRMD dogs.[@bib3] Very low levels of MSTN were measured in the serum of untreated GRMD dogs, suggesting that the Mstn pathway may be intrinsically downregulated in these dogs to counterbalance the wasting process mediated by the absence of dystrophin, as we observed in humans.[@bib15] The GRMD dog is thus a good model to evaluate if components of the Mstn pathway may be used as biomarkers of therapeutic efficacy for DMD. Our results indicate that indeed, MSTN levels may be a reliable biomarker to monitor drug response in neuromuscular patients, including DMD and MTM1 (this work and Mariot et al.[@bib15]). This is based on several observations. (1) We have previously observed in the MTM1-KO mouse model that *M*stn levels are massively decreased compared to controls but increased after MTM1 rescue.[@bib15] (2) Mstn is a blood-based biomarker sensitive to change, as an increase of circulating Mstn occurred only in GRMD dogs systemically treated with a high dose of the cMD1-coding AAV vector. After loco-regional dystrophin rescue in the GRMD dogs, there was an increase of *Mstn* mRNA in the muscle biopsies but no change in circulating Mstn, likely due to the limited systemic effect of only one injected leg. Interestingly, intramuscular injection of the PMO AVI-4658 (eteplirsen) in DMD patients did not lead to an increase of *MSTN*. This is likely due to the fact that only one small foot muscle was injected in this proof-of-principle study and that this muscle only expressed a limited amount of dystrophin (63%--65% of dystrophin-positive fibers with a relative intensity of 22%--25% of that in healthy muscle).[@bib18] (3) MSTN levels are also clinically meaningful and reflect global muscle health. MSTN is mainly produced by the skeletal muscle,[@bib19] and low levels of MSTN reflect not only muscle loss but also poor muscle health, as previously observed in a number of atrophying neuromuscular disorders.[@bib15] (4) MSTN may be a disease agnostic and treatment-agnostic biomarker, as demonstrated here for dystrophin deficiency. (5) There is a progressive decrease of Mstn levels in the long-term follow-up of AAV-treated GRMD dogs, suggesting that MSTN may be of high relevance and particular value for the longitudinal follow-up for treatment efficacy in patients, because contrary to more specific endpoints measured in clinical trials, it will reflect the functional status of the whole neuromuscular system. Indeed, it is known that dystrophin rescue using AAV-mediated microdystrophin can last only a certain time, due to ongoing transgene loss,[@bib20] and a decrease in MSTN levels may indicate that a patient needs to be retreated. However, unlike cohorts classically seen in clinical trials, our dog cohort numbers are too small to draw a definitive picture, but conclusions can be made when considering the convergent picture between clinical and preclinical models.

It is also worth noting that anti-MSTN molecules are currently used in clinical trials in DMD patients ("ClinicalTrials.gov: [NCT03789734](NCT03789734){#intref0030}"). Since circulating MSTN levels can increase after dystrophin rescue, our results also support the concept that patients treated with disease-modifying therapies, capable of substantially ameliorating muscle health, could be better targets for an add-on anti-MSTN therapy than therapy-naive patients, where not only the target for an anti-MSTN therapy itself is low but also, the corresponding ACT2B tissue receptor is downregulated.

In conclusion, the data presented in this study suggest that MSTN is a quantifiable biomarker for monitoring pharmaco-gene therapy in neuromuscular disease, but further studies and clinical trials are needed to demonstrate definitely both the sensitivity of the marker and the capacity of pharmaco-gene therapies to restore the functional capacity of the neuromuscular system. It may be worth measuring MSTN levels in the blood of participants to different current clinical trials aiming at rescuing dystrophin levels using different approaches (such as PMOs, peptide-conjugated PMOs, stereopure antisense oligonucleotides, and AAV-microdystrophin). Indeed, MSTN might complement and eventually replace the need for invasive muscle biopsies usually performed to assess therapy effects in neuromuscular disease.

Materials and Methods {#sec4}
=====================

Ethic Statement and Patient Reports {#sec4.1}
-----------------------------------

All human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The collection of sera and biopsies was approved by ethics committees in each institution. Written, informed consents were provided for each participant. The DMD patients have been described previously.[@bib18]

Animals {#sec4.2}
-------

Dog samples were obtained from the Boisbonne Center for Gene Therapy (ONIRIS; Atlantic Gene Therapies, Nantes, France) and the Institut Mondor de Recherche Biomédicale (IMRB) Team 10 (Ecole Nationale Veterinaire de Maison Alfort, France). Samples coming from the Boisbonne Center have been already described and used previously.[@bib3] The protocol was performed without any immunosuppression regimen.

ELISA Analysis {#sec4.3}
--------------

Dog serum samples were obtained from blood collection after clotting for 30 min at room temperature, followed by a centrifugation for 30 min at 1,000 × *g*. Samples were aliquoted and stored at −80°C until analysis. The ELISA kit was GDF8 (\#DGDF80; R&D Systems Europe, Abingdon, UK), used according to the manufacturer's instructions. The optical density was measured using a microplate reader (Infinite 200 Pro; Tecan Group, Männedorf, Switzerland).

RNA Extraction and Real-Time PCR {#sec4.4}
--------------------------------

Cryopreserved tissues were transferred in tubes containing 1.4 mm ceramic beads (FastPrep; MP Biomedicals, UK) plus 1 mL of TRIzol (Thermo Fisher Scientific, Paisley, UK) and shaken once at 10,000 revolutions per minute (rpm) for 40 s. Total RNA was extracted using TRIzol, according to the manufacturer's protocol (Thermo Fisher Scientific, Paisley, UK). The quantity of RNA was determined using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The reverse transcription was described previously and performed on 1 μg of total RNA in a final volume of 10 μL using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Basel, Switzerland). Quantitative PCRs (qPCRs) were performed on a LightCycler 480 Real-Time PCR System (Roche, Basel, Switzerland) in a final volume of 9 μL with 0.4 μL of reverse transcriptase (RT) product, 0.18 μL each of forward and reverse primers (20 pmol/mL), and 4.5 μL of SYBR Green Mastermix (Roche, Basel, Switzerland). After qPCR, the PCR products were run on a 2% agarose gel and were cloned using the Topo TA cloning kit (Thermo Fisher Scientific, Paisley, UK) and sequenced. qPCR was designed according to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) standards. Primers used in this study are described in [Table S2](#mmc1){ref-type="supplementary-material"}. The transcript amounts were normalized using *Rpl32* dog ribosomal RNA or human *GUS* RNA.

Statistical Analysis {#sec4.5}
--------------------

A one-way ANOVA, followed by Newman-Keuls was used, unless otherwise stated, in the figure legends, with p values of \<0.05 considered significant.
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